Twist Bioscience Corp (TWST – Q2FY20) – Strong growth in revenues due to Synthetic Biology & NGS businesses.

in , on July 31, 2020

Twist Bioscience  introduced a Targeted Methylation Sequencing solution, in February 2020. This product is ideal for customers, focused on liquid biopsy, as it can be used to study methylation pattern changes in a wide range of research fields. The company is working with initial customers and believe it would represent an important area accruals for NGS Solution.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q2FY20 Results – Overview
– Q2FY20 – Revenues & Orders
– Q2FY20–Key Developments
– FY20 Guidance & Conclusion

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Cash Flow Items

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

No of Pages : 38

Release Information

  • Released

    July 31, 2020

  • Last Updated

    July 31, 2020